Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GD2/B7H3 CAR-T for Relapsed/Refractory Neuroblastoma and DSRCT
NCT06836505Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2024
- Primary completion
- Dec 2027
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of GD2/B7H3 CAR-T in neuroblastoma and desmoplastic small round cell tumor (DSRCT), sponsored by Sun Yat-sen University. Primary endpoint: Incidence of adverse events related to CAR-T therapy at 1 year. Started Dec 2024; status: recruiting.
02
Drugs
GD2/B7H3 CAR-T
03
Conditions
neuroblastomadesmoplastic small round cell tumor (DSRCT)
Beyond the preview
Go deeper on NCT06836505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06836505.